Table 28

Overall Survival Meta-Analyses: Epoetin vs. Control; Darbepoetin vs. Control; and Epoetin vs. Control and Darbepoetin Combined

ParameterEpoetin vs. control meta-analysisDarbepoetin vs. control meta-analysisEpoetin + darbepoetin combined meta- analysis
Number of studies35439
Patients analyzed6,9189737,891
HR (95% CI)1.11 (1.00; 1.22)
p=0.05
I2=0%
0.96 (0.78; 1.17)
p=0.66
I2=72.2%
1.08 (0.98; 1.18)
p=0.11
I2=13.4%
HR (95% CI) for subgroups:
Labeled use
Unlabeled use


0.91 (0.47; 1.78)
1.12 (1.01; 1.24)


0.91 (0.47; 1.78)
1.09 (0.99; 1.19)
HR (95% CI) for subgroups:
Max Hb target 12 g/dL
Max Hb target 13 g/dL
Max Hb target 14 g/dL
Max Hb target 15 g/dL
Max Hb target 16 g/dL


(no events)
0.91 (0.47; 1.78)
1.16 (1.00; 1.35)
1.03 (0.90; 1.19)
1.67 (1.13; 2.48)


(no events)
0.91 (0.47; 1.78)
1.16 (1.00; 1.35)
1.01 (0.90; 1.13)
1.67 (1.13; 2.48)
HR (95% CI) for subgroups:
Homogeneous tumor + tx
Not homogeneous tumor + tx


1.26 (1.04; 1.53)
1.06 (0.94; 1.19)


1.06 (0.91; 1.24)
1.08 (0.97; 1.21)

From: 3, Results

Cover of Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment
Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment [Internet].
Comparative Effectiveness Reviews, No. 3.
Seidenfeld J, Piper M, Bohlius J, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.